CRSP / Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week af more_horizontal

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recentl more_horizontal

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings est more_horizontal

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-ed more_horizontal

Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease. more_horizontal

Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: C more_horizontal

Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory deci more_horizontal

CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be rea more_horizontal